Published in Obesity and Diabetes Week, February 28th, 2005
Study 1: Vildagliptin is a dipeptidyl-peptidase IV inhibitor used for the treatment of type 2 diabetes.
"Type 2 diabetes is characterized by chronic hyperglycemia due to the body's progressive inability to efficiently utilize insulin. The majority of individuals who develop this form of diabetes will eventually require drug therapy to control the disease and minimize the risk of complications. The incretin hormone glucagon-like peptide-1 (GLP-1) has a spectrum of effects that mimic the requirements of antidiabetic therapy. This serine protease is degraded...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.